Velan Capital Investment Management LP Sells 11,370 Shares of Abivax SA Sponsored ADR $ABVX

Velan Capital Investment Management LP reduced its stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) by 14.8% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 65,630 shares of the company’s stock after selling 11,370 shares during the period. Abivax accounts for about 5.3% of Velan Capital Investment Management LP’s investment portfolio, making the stock its 7th biggest holding. Velan Capital Investment Management LP owned about 0.08% of Abivax worth $8,746,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. GHP Investment Advisors Inc. raised its position in shares of Abivax by 155.6% during the 1st quarter. GHP Investment Advisors Inc. now owns 230 shares of the company’s stock worth $26,000 after purchasing an additional 140 shares during the period. Versant Capital Management Inc acquired a new stake in Abivax in the second quarter worth $30,000. Assetmark Inc. increased its position in Abivax by 41.5% in the first quarter. Assetmark Inc. now owns 886 shares of the company’s stock worth $99,000 after buying an additional 260 shares during the period. SmartHarvest Portfolios LLC lifted its stake in Abivax by 11.6% in the first quarter. SmartHarvest Portfolios LLC now owns 2,696 shares of the company’s stock valued at $300,000 after buying an additional 280 shares during the last quarter. Finally, Personal CFO Solutions LLC lifted its stake in Abivax by 10.5% in the first quarter. Personal CFO Solutions LLC now owns 3,027 shares of the company’s stock valued at $337,000 after buying an additional 288 shares during the last quarter. 47.91% of the stock is owned by institutional investors.

Abivax Price Performance

NASDAQ ABVX opened at $113.67 on Wednesday. Abivax SA Sponsored ADR has a 12 month low of $69.81 and a 12 month high of $148.83. The firm has a market capitalization of $9.92 billion, a PE ratio of -21.82 and a beta of 0.97. The company’s 50 day simple moving average is $124.95 and its 200 day simple moving average is $118.88.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ABVX. Piper Sandler upped their price target on shares of Abivax from $165.00 to $175.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Wall Street Zen raised shares of Abivax from a “sell” rating to a “hold” rating in a research note on Saturday, May 23rd. Citizens Jmp restated a “market outperform” rating and issued a $187.00 target price on shares of Abivax in a research report on Wednesday, July 1st. Truist Financial raised their price target on shares of Abivax from $135.00 to $155.00 and gave the company a “buy” rating in a research note on Thursday, July 2nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Abivax in a report on Friday, July 17th. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Abivax currently has an average rating of “Moderate Buy” and a consensus price target of $156.50.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.